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Abstract
Background—Screening instruments for obstructive sleep apnea (OSA), as used routinely to 
guide clinicians regarding patient referral for polysomnography (PSG), rely heavily on 
symptomatology. We sought to develop and validate a cerebrovascular disease-specific OSA 
prediction model less reliant on symptomatology, and to compare its performance with commonly 
used screening instruments within a population with ischemic stroke or transient ischemic attack 
(TIA).
Methods—Using data on demographic factors, anthropometric measurements, medical history, 
stroke severity, sleep questionnaires, and PSG from 2 independently derived, multisite, 
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randomized trials that enrolled patients with stroke or TIA, we developed and validated a model to 
predict the presence of OSA (i.e., Apnea-Hypopnea Index ≥5 events per hour). Model 
performance was compared with that of the Berlin Questionnaire, Epworth Sleepiness Scale 
(ESS), the Snoring, Tiredness, Observed apnea, high blood Pressure, Body mass index, Age, Neck 
circumference, and Gender instrument, and the Sleep Apnea Clinical Score.
Results—The new SLEEP Inventory (Sex, Left heart failure, ESS, Enlarged neck, weight [in 
Pounds], Insulin resistance/ diabetes, and National Institutes of Health Stroke Scale) performed 
modestly better than other instruments in identifying patients with OSA, showing reasonable 
discrimination in the development (c-statistic .732) and validation (c-statistic .731) study 
populations, and having the highest negative predictive value of all in struments.
Conclusions—Clinicians should be aware of these limitations in OSA screening instruments 
when making decisions about referral for PSG. The high negative predictive value of the SLEEP 
INventory may be useful in determining and prioritizing patients with stroke or TIA least in need 
of overnight PSG.
Keywords
Ischemic stroke; TIA; Obstructive sleep apnea; Screening
Introduction
Obstructive sleep apnea (OSA) occurs commonly in the post-ischemic stroke or transient 
ischemic attack (TIA) population, affecting 60%–80% of persons after their cerebrovascular 
event.1,2 Untreated OSA is an independent risk factor for future vascular events (e.g., stroke, 
myocardial infarction), may complicate management of vascular risk factors (e.g., 
hypertension, atrial fibrillation), and increases the risk for mortality in patients with 
cerebrovascular disease.3–6 Despite the potential treatment and prognostic implications of 
discovering whether patients with cerebrovascular disease have comorbid OSA, the 
condition frequently goes undiagnosed.5,7 This situation may be due, in part, to the 
observation that hallmark features of OSA (e.g., excessive daytime sleepiness) can occur 
less commonly among patients with cerebrovascular disease than in the general population.5 
Several well-validated sleep instruments used in the general population to screen for OSA 
and perceived somnolence, such as the Berlin Questionnaire (BQ)8 and Epworth Sleepiness 
Scale (ESS) score,6 rely heavily on symptomatic features of OSA, but have not been 
predictive of OSA (as defined by an Apnea-Hypopnea Index [AHI] ≥5 on polysomnography 
[PSG]) in mixed stroke populations (ischemic and hemorrhagic).5,7 A modified version of 
the Snoring, Tiredness, Observed Apnea, high blood Pressure-Body mass index, Age, Neck 
circumference, and Gender (STOP-BANG) was only moderately predictive of OSA 
compared with home sleep testing equipment among patients with a cerebrovascular event,
9,10
 whereas the Sleep Apnea Clinical Score (SACS) has not been studied among patients 
with cerebrovascular disease. Given the suboptimal performance of commonly used OSA 
screening instruments within the stroke or TIA population, authors have suggested that the 
development of models based on medical comorbidity should be pursued.10
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The most recent American Heart Association/American Stroke Association ischemic stroke 
or TIA prevention guidelines provide new recommendations addressing OSA, noting that 
PSG might be considered for patients with an ischemic stroke or TIA and, that once 
diagnosed, treatment of OSA might be considered, given its association with improved post-
cerebrovascular event outcomes.2 The guidelines do not, however, specify which patients 
should be considered for PSG referral. Because universal OSA screening with PSG may not 
be feasible based on the worldwide prevalence of stroke, we sought to (1) develop and 
validate a cerebrovascular disease-specific instrument that would be less reliant on patient 
symptomatology and anthropometric features, and; (2) determine how well the new 
instrument, and the BQ, ESS, SACS, and STOP-BANG, predicted the presence and absence 
of OSA in an exclusively post-ischemic stroke or TIA population (rather than a mixed 
ischemic and hemorrhagic stroke population). These analyses could then help identify which 
patients are most (i.e., high positive predictive value [PPV]) or least (i.e., high negative 
predictive value [NPV]) in need of PSG referral.
Methods
Overview
Participants in 2 separate, multisite, 1-year randomized controlled trials examining the utility 
of unattended PSG to identify and treat OSA in the post-ischemic stroke or TIA populations 
with continuous positive airway pressure (CPAP) were used as the study population; the 
methods of each trial are described elsewhere.11,12 A clinical prediction model was 
developed and validated. Results across different OSA prediction instruments were 
compared.
Patient Populations
From 1 study,11 Veterans with an ischemic stroke within either 30 days of recruitment or any 
time after developing a TIA were included as the development cohort, whereas patients 
(non-Veterans and Veterans) from the second study who had an ischemic stroke or TIA 
within 1 week of enrollment were included as the validation cohort.12 Patients enrolled into 
the study used as the development set had either a history of hypertension or a blood 
pressure ≥140/90 mm Hg. Both studies used the same exclusion criteria: known history of 
OSA, suspected sleep disorder other than OSA (e.g., narcolepsy, given that such patients 
have another indication for formal PSG), life expectancy less than 6 months, inability to use 
either a nasal or a face mask (as continuous positive airway pressure could not be 
administered), non–English-speaking patients, and inability to provide informed consent. 
Patients were not excluded based on stroke severity, or if they had language impairments 
secondary to their event. The BQ, ESS, STOP-BANG, SACS, and National Institutes of 
Health Stroke Scale (NIHSS) scores were calculated for patients after their cerebrovascular 
event.
Definitions
Type 2, full unattended PSG was performed using Safiro Compumedics in both studies. 
Apnea was defined as airflow cessation lasting ≥10 seconds; hypopnea was defined as 
reduction in airflow for ≥10 seconds or decrease in amplitude of breathing by ≥30%, 
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followed by oxygen desaturation ≥3% or arousal from sleep.13 Obstructive events were 
defined as those accompanied by thoracic or abdominal wall movements; central events had 
no associated wall movements. An AHI was calculated from the number of apneas and 
hypopnea per hour; an AHI ≥5 events per hour was used to identify patients with sleep 
apnea.13,14 Excessive daytime sleepiness was defined as an ESS ≥10. “High risk” for OSA 
was defined as scoring positive on 2 or more categories, a SACS ≥15, and by a score ≥5 on 
the STOP-BANG questionnaire.15 As recommended by the Adult Obstructive Sleep Apnea 
Task Force of the American Academy of Sleep Medicine, a large neck was defined as neck 
circumference >17 inches for men and >16 inches for women.16
Development and Validation of Clinical Prediction Model
Rather than dividing a single cohort into a random two-third sample for development and 
retaining the other one-third sample for validation, we used separate, independently derived 
development and validation cohorts. Plots of the logit of sleep apnea by classes of 
continuous predictors were examined to assess the best form of the predictor for modeling. 
Weight, NIHSS, and ESS scores were determined to be modeled as quadratic, whereas 
Personal Health Questionnaire-8 scores had a cubic relationship. Bivariate logistic models 
were then used to assess the strength of each predictor variable. Six variables thought to be 
clinically important were included in the multivariable model: gender, weight, large neck, 
history of congestive heart failure, history of diabetes, and NIHSS score. Six other variables 
(ESS, “high-risk” BQ, chronic obstructive pulmonary disease, Personal Health 
Questionnaire-8, Charlson Comorbidity score, and age) were significant at the .25 level in 
bivariate logistic models and were included in initial models, but were removed by backward 
variable selection if they were not statistically significant at the .05 level. Given the lack of 
association between infarct location and OSA, radiographic data were not included in the 
model.17 Regression diagnostics were performed, and 5 patients were removed from the 
development sample because they proved to be highly influential.
Model performance was evaluated using the c-statistic.18 The optimal cut point for 
predicting OSA was selected as the probability that maximized sensitivity and specificity. 
Resulting classification tables were used to obtain sensitivity, specificity, percentages of 
correctly classified and misclassified, false-positive and false-negative rates, PPVs and 
NPVs, and likelihood ratios for all models.
Missing data were rare; imputation was not used. We used SAS/STAT software, Version 
(9.3) of the SAS system for Windows (Cary, NC). Institutional review board approval was 
obtained for this research.
Results
OSA occurred frequently in the development (119 of 194; 61%) and validation (84 of 109; 
77%) cohorts, as shown in Table 1. Associations between predictor variables and OSA are 
shown in Table 2. The final model included an indicator for female (sex), congestive or left 
heart failure, the ESS, an indicator for having an enlarged neck, weight (in pounds) and 
weight squared, insulin sensitivity or diabetes, and NIHSS score; these factors can be 
combined as the SLEEP INventory, with the NIHSS score and ESS also including squared 
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terms. Although model sensitivity was high in both development (91.4%) and validation 
(100%) cohorts, model specificities were low (development, 43.8%; validation, 12.5%). 
Using the optimal cut point, the percent classified correctly was 73.2% in the development 
sample and 80.2% in the validation sample (data not shown).
As shown in Table 3, the SLEEP INventory, BQ, ESS, STOP-BANG, and SACS had similar 
PPVs; in comparison, the NPV was greatest for the SLEEP INventory (76.2%–100.0%) than 
for the BQ (43.3%), ESS (51.9%–46.2%), STOP-BANG (40.0–41.7), and SACS (12.5%–
44.1%). Alternative models using only the BQ, ESS, STOP-BANG, and SACS typically had 
lower sensitivities, higher specificities, lower rates of classifying cases correctly, and lower 
NPVs. The SLEEP INventory c-statistics were similar between the development and the 
validation sets in modeling the presence of OSA (.732 and .731, respectively).
In examining receiver operator curves for each model, although the SLEEP INventory had 
the best discrimination of any model, none of the models showed strong discrimination 
(Figure 1). Whereas the clinical threshold for treating OSA is an AHI ≥5 events per hour,19 
we also examined how well the SLEEP INventory and other models predicted an AHI index 
≥30 events per hour (i.e., severe OSA)20; the models had similar sensitivities, specificities, 
and predictive values regardless of AHI threshold used (data not shown).
Discussion
This study demonstrates that the BQ, ESS, STOP-BANG, and SACS did not strongly predict 
the presence of OSA on formal PSG in an exclusively post-ischemic stroke or TIA 
population. We also demonstrated that a clinical prediction rule combining patient 
symptomatology with readily available and routinely collected patient demographic, 
anthropometric, medical history, and stroke severity data could be derived from and applied 
to a population of patients with ischemic stroke or TIA. Although the SLEEP INventory 
performed somewhat better than the BQ, ESS, STOP-BANG, and SACS, it too did not 
strongly predict the presence of OSA. Nonetheless, a strength of the SLEEP INventory is in 
its NPV, and it could be used to help prioritize which patients are least in need of PSG 
referral. Our study also confirmed the high rate of OSA in post-stroke or TIA patients, 
occurring in 60%–80% of this population1,21; by comparison, 20%–26% of the general 
population has OSA.22,23
Underdiagnosis of OSA leads to untreated OSA, which is itself a risk factor for stroke, and 
may make other vascular risk factors (e.g., hypertension) more difficult to control.
1,3,4,22,24,25
 Given the importance of identifying individuals at risk for OSA, several 
screening questionnaires have been developed and validated within the general population.
6,8
 The BQ categorized patients as being “high risk” for OSA based on patient-reported 
symptoms (e.g., snoring, tiredness in various settings), body mass index ≥30 kg/m2, and a 
history of hypertension.8 The BQ accurately predicts the presence of OSA on PSG among 
patients in primary care setting (sensitivity 86.0%, specificity 77.0%, PPV 89.0%). The 
accuracy of the BQ was even higher in cardiology clinics (sensitivity 86.0%, specificity 
89.0%, PPV 97.0%).8 When applied to the stroke population (mixed ischemic and 
hemorrhagic), the BQ correlated less well with PSG-defined OSA (sensitivity 68.0%, 
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specificity 59.0%, PPV 59.0%).7 Prediction of OSA was not improved with the addition of 
the ESS (as a measure of daytime somnolence) to the BQ (sensitivity 50.0%, specificity 
88.0%, PPV 57.0%), likely because the BQ already contains questions regarding sleepiness.7 
Srijithesh et al noted that none of the clinical indicators in the BQ were sufficient to 
diagnose OSA in the post-stroke population.7 Boulos et al similarly reported that the BQ did 
not predict the presence of OSA among patients with stroke (mixed ischemic and 
hemorrhagic) or TIA.10 Our current study confirms the lower sensitivity, specificity, and 
predictive values in a study population exclusively with ischemic stroke or TIA, rather than a 
mixed ischemic and hemorrhagic stroke population.
The STOP-BANG has increasingly been used to screen patients for OSA, especially within 
the surgical population. Among preoperative obese patients, a STOP-BANG score of 4 
identified the presence of severe OSA found on PSG with both high sensitivity (87.5%) and 
NPV (90.5%), with a higher score being associated with increased specificity.26 When 
applied to patients with cerebrovascular disease, lower sensitivity (35.3%) and NPV (41.7%) 
were observed in the development and validation sets. Severine et al screened 300 
prospective patients during an admission for a cerebrovascular event for OSA with STOP-
BANG, but information about whether patients were ultimately referred for PSG, and if 
STOP-BANG was associated with the presence of OSA on formal PSG, was not reported.9 
Boulos et al assessed the utility of a modified version of the STOP-BANG (the STOP-BAG, 
which excluded the neck circumference) in detecting the presence of OSA among patients 
with stroke, either ischemic or hemorrhagic, or TIA receiving screening via home sleep 
testing equipment.10 Using cutoffs that maximized sensitivity, the authors reported that the 
STOP-BAG was only moderately predictive of OSA. They also noted that objective sleep 
testing would still be important in diagnosing patients with stroke or TIA with OSA until a 
more accurate instrument was developed, and that future work should focus on developing 
OSA screening instruments that use patient-level comorbidities.10
Like the STOP-BANG, the SACS is another sleep instrument used to make determinations 
about PSG referral that has its origins in perioperative OSA assessment. The SACS includes 
patient symptomatology, neck circumference, and a history of hypertension; it has been 
found to have a sensitivity of 76% and a PPV of 77% when applied to patients presenting to 
a sleep disorders center.15,27 To our knowledge, the SACS has not been used to predict OSA 
on PSG for patients with cerebrovascular disease. Our findings suggest that the SACS likely 
has limited utility in the stroke or TIA population.
As described above, the BQ, ESS, STOP-BANG, and SACS rely heavily on patient 
symptomatology and anthropometric features, but excessive daytime sleepiness and obesity 
may occur less commonly among patients with ischemic stroke than in a community sample 
of patients without a stroke. In a case-control study, Arzt et al sought to determine whether 
post-ischemic and hemorrhagic stroke patients reported less daytime sleepiness, and had 
lower body mass indexes, than did a community sample of persons with a similar degree of 
OSA.5 Patients with stroke and OSA were statistically less likely to have a high ESS (10% 
versus 38%; P < .001) and to be obese (26% versus 70%; P < .001). The authors noted that 
sleepiness is an uncommon feature of OSA, and that obesity seemed less likely to contribute 
to the development of OSA among patients with cerebrovascular disease.21 Interestingly, our 
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study demonstrated that the relationship between ESS values and the log odds of sleep apnea 
is not linear, but quadratic, with higher ESS scores associated with a decreased likelihood of 
OSA in the stroke population. Conceivably, patients with stroke who are excessively sleepy 
may be so for reasons other than OSA (e.g., direct impact of stroke, use of antihypertensive 
medications). Explanations for this difference between our findings and those of Arzt et al 
may be because we used an exclusively post-ischemic stroke or TIA population, rather than 
a combination of ischemic and hemorrhagic stroke patients. Also, we found that the 
relationship between ESS and OSA is more complex than perhaps previously appreciated; 
similar to other studies, when we used the ESS as a binary variable, it was not predictive of 
OSA (data not shown).5
In applying these data to the patient with ischemic stroke or TIA, the PPV and NPVs of the 
OSA screening instruments should be considered. Given that the prevalence of OSA among 
patients with stroke and TIA exceeds 50%, it is reasonable for clinicians to presume that 
their patient with cerebrovascular disease has OSA. In this situation, the NPV, or the 
probability that an individual does not have OSA based on a negative screening result, 
becomes important in assessing the clinical usefulness of the screening instrument. Based on 
the current results, the SLEEP INventory, having the greatest NPV in the cerebrovascular 
disease population compared with other models, could be used clinically to aid 
determinations regarding which patients might not need referral.
The strengths of our study include our large sample size, having separate development and 
validation cohorts in which to generate and validate our clinical prediction model, and 
having complete PSG study data on all patients in the development cohort. The development 
set included chronic post-stroke or TIA patients, whereas the validation cohort included 
patients with acute ischemic stroke. Combined, these 2 cohorts encompass post-stroke or 
TIA patients across the continuum of their care in non-Veterans and Veterans health-care 
settings, thereby increasing the generalizability of our model. Additionally, we examined the 
utility of OSA prediction models exclusively among patients with an ischemic stroke or 
TIA, rather than a mixed population of patients with ischemic and hemorrhagic stroke.6,8,10 
Finally, the SACS has not been previously examined among patients with cerebrovascular 
disease.
Several limitations should be noted. First, we defined OSA as an AHI ≥5 events per hour 
documented on PSG (based on American Academy of Sleep Medicine guidelines)14,15,28; 
other studies have examined alternative AHI values (e.g., AHI ≥ 10) to identify OSA 
presence.7,10 Of note, the SLEEP INventory performed equally in regard to predicting AHI 
≥5 and ≥30 in the current analysis. Second, when both the BQ and the SACS were 
developed, the authors found hypertension to be predictive of OSA,8,15 whereas our 
development cohort consisted entirely of patients with hypertension (and we were therefore 
unable to model hypertension in our current work). Third, these data came from 2 
randomized trials, and are subject to issues of generalizability related to study design.29,30 
Fourth, there is a paucity of validated screening tools for patients older than the age of 75; 
future work should seek to validate our findings within a cohort of exclusively older patients. 
Finally, we recognize that our model may be more complex to implement in a clinic setting 
compared with the BQ, ESS, STOP-BANG, or SACS. Feasible options to help providers 
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make determinations about prioritizing PSG by incorporating the SLEEP INventory into the 
workflow of a busy clinic to referrals include integrating it into an existing EHR, developing 
a separate online SLEEP INventory calculator, and having this screening instrument as part 
of a nursing intake for stroke patients at follow-up.
Conclusions
This study confirmed the high prevalence of previously undiagnosed OSA and reported the 
limited utility of the BQ, ESS, STOP-BANG, and SACS as OSA screening instruments for 
patients with an ischemic stroke or TIA. Given the high prevalence and potential treatment 
implications in discerning whether a patient with a cerebrovascular event has OSA, if 
clinicians presume that their patient has OSA, the SLEEP INventory (with its NPV) may 
help make determinations regarding which patients are least in need of sleep center referral. 
However, this approach would still misclassify approximately 25% of all patients with a 
cerebrovascular event as not having OSA, suggesting that in a population where OSA is 
exceedingly prevalent and difficult to screen for, there likely is an important role for formal 
sleep testing (e.g., PSG).
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Figure 1. 
Receiving operator curves for SLEEP INventory and other predictors of obstructive sleep 
apnea
Sico et al. Page 10
J Stroke Cerebrovasc Dis. Author manuscript; available in PMC 2018 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Sico et al. Page 11
Ta
bl
e 
1
Ch
ar
ac
te
ris
tic
s o
f p
at
ie
nt
s i
n 
th
e 
de
v
el
op
m
en
t a
nd
 v
al
id
at
io
n 
co
ho
rts
D
ev
el
op
m
en
t s
et
P-
v
a
lu
e
Va
lid
at
io
n 
se
t
P-
v
a
lu
e
O
SA
 p
re
se
n
t
O
SA
 a
bs
en
t
O
SA
 p
re
se
n
t
O
SA
 a
bs
en
t
Ch
ar
ac
te
ris
tic
s
n
 =
 1
19
n
 =
 7
5
n
 =
 8
4
n
 =
 2
5
D
em
og
ra
ph
ic
A
ge
 (y
)
 
M
ea
n 
± 
SD
70
.8
 ±
 9
.9
68
.7
 ±
 1
0.
6
.
18
60
.7
 ±
 1
1.
5
55
.5
 ±
 1
4.
0
.
13
 
M
ed
ia
n 
(m
in,
 m
ax
)
71
 (4
8, 
91
)
68
 (4
5, 
88
)
60
 (3
2, 
94
)
59
 (3
0, 
80
)
R
ac
e
 
W
hi
te
10
0 
(84
.0%
)
59
 (7
8.7
%)
.
56
52
 (6
1.9
%)
19
 (7
6.0
%)
.
24
 
B
la
ck
18
 (1
5.1
%)
15
 (2
0.0
%)
30
 (3
5.7
%)
6 
(24
.0%
)
 
O
th
er
1 
(.8
%)
1 
(1.
3%
)
2 
(2.
4%
)
0 
(.0
%)
G
en
de
r
 
M
al
e
11
7 
(98
.3%
)
71
 ((
94
.7%
)
.
21
56
 (6
6.7
%)
14
 (5
6.0
%)
.
33
A
nt
hr
op
om
et
ric
H
ei
gh
t (
m)
 
M
ea
n 
± 
SD
1.
7 
± 
.1
1.
8 
± 
.1
.
48
1.
7 
± 
.1
1.
7 
± 
.1
.
28
 
M
ed
ia
n 
(m
in,
 m
ax
)
1.
8 
(1.
6, 
1.9
)
1.
8 
(1.
5, 
1.9
)
1.
7 
(1.
3, 
1.9
)
1.
7 
(1.
6, 
1.9
)
W
ei
gh
t (
kg
)
 
M
ea
n 
± 
SD
87
.7
 ±
 1
4.
8
84
.8
 ±
 1
6.
4
.
21
88
.9
 ±
 2
0.
6
84
.7
 ±
 1
9.
7
.
28
 
M
ed
ia
n 
(m
in,
 m
ax
)
86
 (5
7, 
12
9)
83
 (5
0, 
12
8)
88
.8
 (5
4.4
, 1
36
)
82
.1
 (5
9, 
14
5)
B
M
I
 
M
ea
n 
± 
SD
44
.3
 ±
 1
1.
9
42
.9
 ±
 1
2.
6
.
39
30
.4
 ±
 7
.0
29
.9
 ±
 8
.7
.
41
 
M
ed
ia
n 
(m
in,
 m
ax
)
46
.9
 (1
8.0
, 6
9.7
)
42
.9
 (1
6.0
, 7
1.1
)
29
.1
 (1
6.4
, 5
1.5
)
28
.0
 (2
0.8
, 5
8.8
)
La
rg
e 
ne
ck
 c
irc
um
fe
re
nc
e
 
Ye
s
30
 (2
5.2
%)
15
 (2
0.3
%)
.
43
23
 (2
7.7
%)
0 
(.0
%)
.
00
3
 
N
o
89
 (7
4.8
%)
59
 (7
9.7
%)
60
 (7
1.4
%)
25
 (1
00
%)
W
ai
st 
ci
rc
um
fe
re
nc
e 
(cm
)
 
M
ea
n 
± 
SD
10
7.
1 
± 
12
.7
10
4 
± 
12
.9
.
15
10
7.
7 
± 
14
.6
10
1.
6 
± 
14
.2
.
02
 
M
ed
ia
n 
(m
in,
 m
ax
)
10
7 
(78
, 1
42
)
10
3 
(71
, 1
30
)
11
0 
(76
.5,
 14
5)
99
 (8
1.5
, 1
35
.3)
J Stroke Cerebrovasc Dis. Author manuscript; available in PMC 2018 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Sico et al. Page 12
D
ev
el
op
m
en
t s
et
P-
v
a
lu
e
Va
lid
at
io
n 
se
t
P-
v
a
lu
e
O
SA
 p
re
se
n
t
O
SA
 a
bs
en
t
O
SA
 p
re
se
n
t
O
SA
 a
bs
en
t
M
ed
ic
al
 h
ist
or
y
Is
ch
em
ic
 st
ro
ke
71
 (5
9.7
%)
36
 (4
8.0
%)
–
13
 (1
5.5
%)
6 
(24
.0%
)
–
TI
A
32
 (2
6.9
%)
25
 (3
3.3
%)
–
6 
(7.
1%
)
1 
(4.
0%
)
–
Is
ch
em
ic
 st
ro
ke
 o
r 
TI
A
16
 (1
3.5
%)
14
 (1
8.7
%)
.
27
4 
(4.
8%
)
0 
(.0
%)
.
68
H
yp
er
te
ns
io
n
11
9 
(10
0%
)
75
 (1
00
%)
–
51
 (6
0.7
%)
14
 (5
6.0
%)
.
67
H
yp
er
lip
id
em
ia
10
3 
(86
.6%
)
55
 (7
3.3
%)
.
02
47
 (5
6.6
%)
12
 (4
8.0
%)
.
45
D
ia
be
te
s
52
 (4
3.7
%)
25
 (3
3.3
%)
.
15
22
 (2
6.2
%)
8 
(32
.0%
)
.
57
 
w
ith
 e
nd
 o
rg
an
 c
o
m
pl
ic
at
io
ns
21
 (1
7.6
%)
9 
(12
.0%
)
.
29
9 
(10
.7%
)
2 
(8.
0%
)
.
42
A
tri
al
 fi
br
ill
at
io
n
19
 (1
6.0
%)
11
 (1
4.7
%)
.
81
8 
(9.
5%
)
1 
(4.
0%
)
.
68
Co
ng
es
tiv
e 
he
ar
t f
ai
lu
re
14
 (1
1.8
%)
6 
(8.
0%
)
.
40
5 
(6.
0%
)
2 
(8.
0%
)
.
65
M
yo
ca
rd
ia
l i
nf
ar
ct
io
n
28
 (2
3.5
%)
20
 (2
6.7
%)
.
62
17
 (2
0.2
%)
2 
(8.
0%
)
.
23
D
em
en
tia
10
 (8
.4%
)
5 
(6.
7%
)
.
66
1 
(1.
2%
)
0 
(.0
%)
–
Po
ly
su
bs
ta
nc
e 
us
e
Sm
ok
in
g 
or
 sm
ok
ed
85
 (7
1.4
%)
62
 (8
2.7
%)
.
08
54
 (6
4.3
%)
16
 (6
4.0
%)
.
98
Co
ca
in
e 
us
e 
or
 u
se
d
11
 (9
.2%
)
11
 (1
4.7
%)
.
25
15
 (1
7.9
%)
4 
(16
.0%
)
.
99
Ch
ar
lso
n 
Co
m
or
bi
di
ty
 sc
or
e
 
M
ea
n 
± 
SD
2.
4 
± 
2.
1
2.
6 
± 
2.
4
.
67
2.
0 
± 
2.
1
2.
0 
± 
2.
0
.
90
 
M
ed
ia
n 
(m
in,
 m
ax
)
2 
(0,
 11
)
2 
(0,
 12
)
2.
0 
(0,
 9)
1.
0 
(0,
 6)
M
od
ifi
ed
 R
an
ki
n
 
M
ea
n 
± 
SD
1.
1 
± 
1.
3
1.
2 
± 
1.
2
.
49
1.
6.
 ±
 1
.3
1.
5 
± 
1.
2
.
69
 
M
ed
ia
n 
(m
in,
 m
ax
)
1 
(0,
 4)
1 
(0,
 4)
1 
(0,
 4)
1 
(0,
 4)
PH
Q-
8
 
M
ea
n 
± 
SD
6.
0 
± 
5.
3
7.
5 
± 
5.
8
.
05
5.
0 
± 
4.
3
6.
4 
± 
4.
6
.
14
 
M
ed
ia
n 
(m
in,
 m
ax
)
5 
(0,
 21
)
6 
(0,
 23
)
3 
(0,
 18
)
6 
(0,
 18
)
N
eu
ro
lo
gi
ca
l s
ym
pt
om
s
N
IH
SS
 sc
or
e
 
M
ea
n 
± 
SD
1.
8 
± 
2.
7
1.
8 
± 
2.
1
.
36
1.
9 
± 
2.
2
2.
3 
± 
2.
2
.
30
 
M
ed
ia
n 
(m
in,
 m
ax
)
1 
(0,
 13
)
1 
(0,
 9)
1 
(0,
 12
)
2 
(0,
 8)
Sl
ee
p 
in
v
en
to
rie
s
ES
S
J Stroke Cerebrovasc Dis. Author manuscript; available in PMC 2018 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Sico et al. Page 13
D
ev
el
op
m
en
t s
et
P-
v
a
lu
e
Va
lid
at
io
n 
se
t
P-
v
a
lu
e
O
SA
 p
re
se
n
t
O
SA
 a
bs
en
t
O
SA
 p
re
se
n
t
O
SA
 a
bs
en
t
 
M
ea
n 
± 
SD
7.
6 
± 
4.
4
7.
1 
± 
5.
8
.
15
7.
0 
± 
4.
3
6.
3 
± 
5.
2
.
39
 
M
ed
ia
n 
(m
in,
 m
ax
)
7 
(0,
 22
)
5 
(0,
 20
)
7 
(0,
 21
)
6 
(0,
 18
)
 
H
ig
h 
ris
k
40
 (3
3.6
%)
23
 (3
0.7
%)
.
67
17
 (2
0.2
%)
6 
(24
.0%
)
.
73
B
Q
 
H
ig
h 
ris
k
85
 (7
1.4
%)
49
 (6
5.3
%)
.
37
56
 (6
6.7
%)
14
 (5
6.0
%)
.
46
SA
CS
 
M
ea
n 
± 
SD
19
.7
 ±
 1
5.
9
16
.2
 ±
 1
2.
5
.
07
14
.1
 ±
 1
9.
1
5.
1 
± 
4.
6
.
00
2
 
M
ed
ia
n 
(m
in,
 m
ax
)
16
 (1
, 1
10
)
13
 (3
, 8
0)
8 
(0,
 11
0)
4 
(0,
 22
)
SA
CS
 ≥
 1
5
62
 (5
2.1
%)
28
 (3
7.3
%)
.
04
25
 (2
9.8
%)
1 
(4.
0%
)
.
00
8
ST
O
P-
BA
N
G
 
M
ea
n 
± 
SD
3.
9 
± 
1.
0
3.
8 
± 
.8
.
63
3.
9 
± 
1.
5
3.
0 
± 
1.
2
.
00
6
 
M
ed
ia
n 
(m
in,
 m
ax
)
4 
(2,
 6)
4 
(1,
 6)
4 
(1,
 8)
3 
(1,
 6)
B
M
I, 
bo
dy
 m
as
s i
nd
ex
; B
Q,
 B
erl
in 
Qu
est
ion
na
ire
; E
SS
, E
pw
o
rt
h 
Sl
ee
pi
ne
ss
 S
ca
le
; N
IH
SS
, N
at
io
na
l I
ns
tit
ut
es
 o
f H
ea
lth
 S
tro
ke
 S
ca
le
; O
SA
, o
bs
tru
ct
iv
e 
sle
ep
 a
pn
ea
; P
H
Q,
 Pa
tie
nt
 H
ea
lth
 Q
ue
sti
on
na
ire
; 
SA
CS
, S
le
ep
 A
pn
ea
 C
lin
ic
al
 S
co
re
; S
D
, s
ta
nd
ar
d 
de
v
ia
tio
n;
 T
IA
, t
ra
ns
ie
nt
 is
ch
em
ic
 a
tta
ck
.
J Stroke Cerebrovasc Dis. Author manuscript; available in PMC 2018 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Sico et al. Page 14
Table 2
SLEEP INventory development: predictors of sleep apnea in patients with stroke or TIA
OR (95% CI)
Development Validation
Covariates (n = 188) (n = 106)
Female .10 (.01, 1.04) .90 (.31, 2.61)
Weight 1.02 (1.00, 1.05) 1.00 (.97, 1.03)
Weight squared 1.000 (.999, 1.001) 1.000 (.999, 1.001)
Large neck 1.10 (.41, 3.00)
–
*
Congestive heart failure 1.16 (.40, 3.37) .59 (.05, 6.53)
Diabetes 1.71 (.85, 3.43) .69 (.22, 2.17)
NIH Stroke Scale .57 (.34, .96) .74 (.43, 1.25)
NIHSS squared 1.09 (1.00, 1.20) 1.03 (.97 1.09)
Epworth 1.47 (1.17, 1.85) 1.23 (.90, 1.67)
Epworth squared .98 (.97, .99) .99 (.98, 1.01)
C-statistic .732 .731
Predicted probability
Cutoff for classification .465 .465
Sensitivity 106/116 (91.4%) 82/82 (100%)
False-negative rate 10/116 (8.6%) 0/82 (.0%)
Specificity 32/73 (43.8%) 3/24 (12.5%)
False-positive rate 41/73 (56.2%) 21/24 (87.5%)
Classified correctly 138/189 (73.2%) 85/106 (80.2%)
Misclassified 51/189 (27.0%) 21/106 (19.1%)
CI, confidence interval; OR, odds ratio; SD, standard deviation; TIA, transient ischemic attack.
*Not able to estimate because no patients without sleep apnea had a large neck.
Regression diagnostics showed 5 subjects in the development sample to be overly influential, so they were not included in the final predictive 
model. One subject in the development sample had missing values for explanatory variables and was omitted from modeling. Three subjects in the 
validation sample had missing values for explanatory variables and were not included in modeling.
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